ReviewHepatobiliary surgery and nutrition2022
Cholangiocarcinoma: a review of the literature and future directions in therapy.
Review in Hepatobiliary surgery and nutrition, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it, 47 citations in OpenAlex.
- Prognostic role of C-reactive protein-albumin-lymphocyte (CALLY) index in gastrointestinal malignancies: a systematic review and meta-analysis.BMC gastroenterology · 2026Pooled it
- A practical nomogram for predicting survival in patients with extrahepatic cholangiocarcinoma: a population-based cohort study.Journal of gastrointestinal oncology · 2026Article
- ALPPS for perihilar cholangiocarcinoma in a patient with cirrhosis and cardiopulmonary comorbidities: a case report.International journal of surgery case reports · 2026Article
- ERBB2 mutations promote recurrence and metastasis in non-muscle-invasive bladder cancer via HIF-1 phosphorylation: Insights from whole exome sequencing.Journal of pharmaceutical analysis · 2026Article
- Expanding Horizons in Cholangiocarcinoma: Emerging Targets Beyond FGFR2 and IDH1.International journal of molecular sciences · 2025Review
- Outcomes of Living-Donor Liver Transplantation for Cholangiocarcinoma Versus Hepatocellular Carcinoma in the United States.Journal of clinical medicine · 2025Article
- Exceptional tumor-free survival of a patient with metastatic intrahepatic cholangiocarcinoma after surgery and personalized peptide vaccination: revisiting a striking case.Journal for immunotherapy of cancer · 2025Article
- Comparison of prognostic factors and their differences in intrahepatic, hilar, and distal cholangiocarcinoma: A systematic review and meta-analysis.World journal of gastrointestinal oncology · 2025Article
- EZH2-Mediated PHF10 Suppression Amplifies HMGB1/NF-κB Axis That Confers Chemotherapy Resistance in Cholangiocarcinoma.Journal of cellular and molecular medicine · 2025Article
- Novel Insights into PGM2L1 as a Prognostic Biomarker in Cholangiocarcinoma: Implications for Metabolic Reprogramming and Tumor Microenvironment Modulation.International journal of medical sciences · 2025Article
- Aberrant ALPP Expression Serves as a Prognostic Biomarker and Facilitates Cholangiocarcinoma Progression through Immune Evasion and PI3K-Akt Signaling Activation.International journal of medical sciences · 2025Article
- Drug-free remission of immune thrombocytopenic purpura following resection of perihilar cholangiocarcinoma: a case report.Journal of surgical case reports · 2024Article
- Machine learning to predict the early recurrence of intrahepatic cholangiocarcinoma: A systematic review and meta‑analysis.Oncology letters · 2024Article
- Investigation of transcriptional and immunological disparities among patient groups with varied prognostic risk factors in cholangiocarcinoma.Cancer medicine · 2024Article
- Residual biliary intraepithelial neoplasia without malignant transformation at resection margin for perihilar cholangiocarcinoma does not require expanded resection: a dual center retrospective study.World journal of surgical oncology · 2024Article
- Octamer-binding transcription factor 4-positive circulating tumor cell predicts worse treatment response and survival in advanced cholangiocarcinoma patients who receive immune checkpoint inhibitors treatment.World journal of surgical oncology · 2024Article
- Current interventional options for palliative care for patients with advanced-stage cholangiocarcinoma.World journal of clinical oncology · 2024Review
- Review
- Article
- Clinical Outcomes of Robotic Resection for Perihilar Cholangiocarcinoma: A First, Multicenter, Trans-Atlantic, Expert-Center, Collaborative Study.Annals of surgical oncology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cholangiocarcinomas (CCA) are a group of rare cancers with an incidence of about 1.26 per 100,000 people. The disease reflects one of three different subtypes: intrahepatic, perihilar or hilar and distal cholangiocarcinoma. The preferred modality of definitive therapy is surgical resection with or without adjuvant therapy, however the majority of patients with this disease do not present at an early stage. Some efforts to improve survival rates have come in the form of offering neoadjuvant therapy prior to surgical resection or liver transplantation. Some new protocols are in the process of development for neoadjuvant therapy. Despite advancements in locally advanced or borderline resectable lesions, most patient present at an advanced stage. The mainstay of treatment for advanced stage disease is chemotherapy regardless of location. The mainstay of treatment in fit patients is the combination of gemcitabine and cisplatin. The addition of nab-paclitaxel to this backbone is currently being evaluated in phase III trial. In addition, the role of targeted therapy is currently being studied extensively through multiple different mutational pathways including isocitrate dehydrogenase-1 (IDH1), fibroblast growth factor receptor (FGFR), epidermal growth factor receptor (EGFR) and ERBB2 (HER2/neu). CCA remains a significant challenge in medicine, however recent studies have shown that there is significant interest in advancing therapy in the form of neoadjuvant, adjuvant and palliative intent treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.